Improving Lives Through Nuclear Medicine™

Medical and R&D

Investigator Initiated Research

In pursuit of our mission to improve patient lives, Jubilant Radiopharma is dedicated to the enhanced utility and accelerated growth of nuclear medicine and molecular imaging.  As part of this commitment, we support innovative clinical studies that address important medical and scientific questions related to our diagnostic and therapeutic areas of interest.

In addition to conducting our own clinical research, we actively seek external requests for support of Investigator Initiated Research that is initiated, designed and sponsored by external researchers. We consider such requests for support based on scientific merit and strategic fit with our areas of research interest. These reviews are carried out by our global network of medical and scientific team members. Decisions are based upon scientific merit, alignment with research areas of interest and availability of resources.

At the time of this posting the areas of research interest are:

  • Advanced Functional Lung Imaging (V/Q) with SPECT/CT in COVID population

    Evaluate recovering or post-positive COVID-19 patient population utilizing SPECT/CT V/Q with DTPA and MAA, prior to or in early treatment stage and again one-month post treatment to monitor and measure patient management.   

  • Cardiac PET

    New clinical data to support quantitative flow assessment, utility in triaging acute chest pain patients, infusion profile preferences and novel uses of Rubidium-82.
  • Neuroblastoma

  • Radioiodine Therapy

If you are interested in collaborating with us on these or other topics of interest, please contact our medical affairs department at medicalaffairs@jdi.jubl.com or fill out the Investigator Sponsored Trial Application Form here and return to our Medical Affairs Department.

Investigator Initiated Research is an unsolicited, independent research project where the investigator or the institution serves as the Sponsor and Jubilant Radiopharma provides support in the form of product or funding. Jubilant is not the sponsor and the investigator and institution/organization assumes all legal and regulatory responsibilities as a sponsor-investigator.

*Research requests will be evaluated by committee on a monthly basis.  Submissions do not necessarily guarantee support. Jubilant Radiopharma has sole discretion to accept or reject a request. 

We use cookies to recognize your repeat visits and preferences, as well as to measure the effectiveness
of campaigns and analyze traffic. If you continue to use this site we will assume your acceptance.